Squaraine-based I-type photosensitizer as well as preparation method and application thereof

By developing a type I photosensitizer based on cyanine, using tetrastyrene-substituted indoline derivatives and nanoparticle technology, the problem of insufficient reactive oxygen generation capacity of existing photosensitizers in an oxygen-deficient environment is solved, and high efficiency is achieved photodynamic/photothermal combined therapy effect.

CN118930471AActive Publication Date: 2024-11-12HUAZHONG UNIV OF SCI & TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410983140.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Existing photosensitizers have poor solubility and strong aggregation characteristics under physiological environment, resulting in low reactive oxygen generation efficiency and high oxygen dependence, which affects the therapeutic effect.

Method used

Develop a type I photosensitizer based on cyanine, using tetrastyrene-substituted indoline derivatives as donors, using cyanine as receptors, and improving their inability to use cyanine as a specific synthesis method and nanoparticle assembly technology. Reactive oxygen generation capacity and photothermal conversion efficiency in an oxygen environment.

Benefits of technology

It achieves efficient generation of reactive oxygen species and calories in an oxygen-deficient environment, reduces the reduction in reactive oxygen generation capacity caused by aggregation, has good light/thermal stability and biocompatibility, and is suitable for photodynamic/photothermal combined treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930471A_ABST
    Figure CN118930471A_ABST
Patent Text Reader

Abstract

The invention relates to a squarylium cyanine-based I-type photosensitizer as well as a preparation method and application thereof, and belongs to the technical field of preparation of chemical materials and biomedical nano materials. The molecular structure of the I-type photosensitizer provided by the invention takes a tetraphenyl ethylene substituted indoline derivative as a donor and squaric acid as an acceptor. Wherein the rotor structure of tetraphenyl ethylene can effectively avoid compact pi-pi accumulation among molecules. The I-type photosensitizer disclosed by the invention has the advantages of high molar absorption coefficient, good light stability, low biotoxicity and the like, and also shows efficient I-type active oxygen (. OH) generation capability and photo-thermal conversion capability (54.2%), so that the I-type photosensitizer can be used for photodynamic / photo-thermal combined anti-tumor and antibacterial treatment. In photodynamic / photo-thermal combined therapy, after laser irradiation, the I-type photosensitizer can simultaneously generate a large amount of active oxygen (. OH) and heat, and tumor cells and bacteria can be efficiently killed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of preparation of chemical materials and biomedical nanomaterials, and more specifically, relates to a type I photosensitizer based on squarylium cyanide and a preparation method and application thereof. Background Art

[0002] Phototherapy strategies have become an effective tumor treatment method in recent years due to their advantages such as being non-invasive, spatiotemporally controllable, drug-resistant and with few toxic side effects. They mainly include photodynamic therapy (PDT) and photothermal therapy (PTT). Specifically, PDT is a process in which a photosensitizer in a triplet state reacts with surrounding substrates (such as O2 or H2O) under laser excitation of a specific wavelength to produce toxic reactive oxygen species (ROS) to kill cancer cells. Depending on the type of ROS produced, photosensitizers are divided into type I (generating ·OH or ·O2 - ) and type II (generated 1 O2). Currently, most organic photosensitizers mainly produce type II reactive oxygen species, which are highly oxygen-dependent. The hypoxic characteristics in the microenvironment will affect their therapeutic effects. Compared with type II photosensitizers, type I photosensitizers are less dependent on oxygen and have greater therapeutic potential in hypoxic microenvironments. Therefore, the development of type I photosensitizers is of great significance. PTT refers to a therapeutic strategy that converts light into heat. Molecules in an excited state return to the ground state through non-radiative transitions and release heat, inducing a local temperature rise and killing cells. Compared with single PDT or PTT, PDT / PTT combined therapy can effectively reduce the heat required for treatment and the lack of sensitivity of certain cancer cells to ROS, thereby significantly reducing the survival rate of heat-resistant cells and the side effects of high-dose drugs.

[0003] The commonly used organic photosensitizers (such as porphyrin, phthalocyanine, etc.) have strong structural rigidity, poor solubility under physiological conditions, and strong aggregation characteristics, which easily lead to a significant reduction in the efficiency of active oxygen generation, resulting in poor photodynamic sterilization effect. Therefore, the existing technology needs further improvement and development. Summary of the invention

[0004] The present invention solves the technical problems of the photosensitizer in the prior art, such as the complicated preparation method, difficulty in modification, poor biocompatibility, decreased reactive oxygen generation capacity due to aggregation, and single function, and provides a type I photosensitizer and its preparation method and application. The type I photosensitizer uses an indoline derivative substituted with tetraphenylethylene as a donor and a squaric acid as an acceptor. The type I photosensitizer has the technical advantages of simple synthesis, low biological toxicity, good light / heat stability, excellent reactive oxygen generation capacity and photothermal conversion efficiency.

[0005] According to the first aspect of the present invention, a type I photosensitizer based on squarylium is provided, wherein the type I photosensitizer uses a tetraphenylethylene-substituted indoline derivative as a donor and squarylium as an acceptor; the structural formula of the type I photosensitizer is shown in formula I:

[0006]

[0007] Wherein, R1 is selected from one of CH3, CH2SO3Na and CH2SO3K; R2 is selected from one of H, OCH3, -N(CH3)2 and -N(C6H5)2.

[0008] According to another aspect of the present invention, a method for preparing the type I photosensitizer based on squarylium cyanine is provided, comprising the following steps:

[0009] (1) dissolving the compound of formula II and 3,4-dihydroxy-3-cyclobutene-1,2-dione in a mixed organic solvent, wherein the mixed organic solvent is a mixed solvent of a benzene organic solvent and an alcohol organic solvent;

[0010] (2) reacting the mixed solvent obtained in step (1) at 100-140° C., and after sufficient reaction, purifying the mixed solvent. When R1 is CH2SO3Na or CH2SO3K, it is also necessary to undergo sodium ionization or potassium ion treatment accordingly, thereby obtaining a type I photosensitizer based on squarylium cyanide having a structural formula as shown in Formula I;

[0011]

[0012] Wherein, R1 is selected from one of CH3, CH2SO3Na and CH2SO3K; R2 is selected from one of H, OCH3, -N(CH3)2 and -N(C6H5)2.

[0013] Preferably, the benzene organic solvent is benzene, toluene or xylene, and the alcohol organic solvent is propanol, n-butanol or n-pentanol.

[0014] Preferably, the molar ratio of the compound of formula II to 3,4-dihydroxy-3-cyclobutene-1,2-dione is (2-2.4):1.

[0015] Preferably, the concentration of the compound of formula II in the mixed organic solvent is 1 mg / mL to 10 mg / mL.

[0016] Preferably, in step (2), the reaction time is 8-24 hours.

[0017] According to another aspect of the present invention, there is provided the use of the type I photosensitizer based on squaryl cyanine for preparing a photodynamic and photothermal combined anti-tumor preparation or a photodynamic and photothermal combined antibacterial preparation, wherein the type I photosensitizer based on squaryl cyanine is assembled to obtain nanoparticles with a core-shell structure.

[0018] Preferably, the type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide are added to an organic solvent miscible with water, added to water under ultrasonic conditions, and then ultrasonically treated to assemble the type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide to obtain nanoparticles with a core-shell structure, and then dialyzed to remove the organic solvent to obtain a mixed system of nanoparticles and water.

[0019] Preferably, the mass ratio of the type I photosensitizer based on squarylium cyanine to the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide is 1:(2-20).

[0020] Preferably, the concentration of the nanoparticles in the mixed system is 0.1 mg / mL to 0.2 mg / mL.

[0021] In general, the above technical solution conceived by the present invention has the following technical advantages compared with the prior art:

[0022] (1) Squarylium phthalocyanine has the characteristics of strong absorption in the visible / near-infrared region, high molar absorption coefficient, low biological toxicity, easy synthesis and good chemical / photostability. In addition, tetraphenylethylene has a propeller-shaped conformation in structure. This unique propeller structure is more likely to stack in a disordered manner under physiological conditions, thereby effectively inhibiting the strong π-π stacking within / between molecules. Moreover, this rotor structure can still maintain local rotation / vibration even when aggregated, which is conducive to dissipating excited state energy through non-radiative pathways. Therefore, introducing tetraphenylethylene into the phthalocyanine system can effectively avoid aggregation and lead to a decrease in the ability to generate active oxygen.

[0023] (2) The type I photosensitizer nanoparticles prepared by the present invention can effectively avoid the problem of aggregation leading to a decrease in the ability to produce reactive oxygen species under physiological conditions, showing that aggregation enhances the ability to produce reactive oxygen species and has good photodynamic properties.

[0024] (3) The active oxygen generated by the type I photosensitizer nanoparticles prepared by the present invention is ·OH, which can effectively avoid the degradation of photodynamic performance in an oxygen-deficient environment and has more advantages in practical applications.

[0025] (4) The type I photosensitizer nanoparticles prepared by the present invention have excellent photothermal conversion ability. The photothermal conversion efficiencies of the type I photosensitizers TPE-SQ6 NPs and TPE-SQ7 NPs of the present invention are calculated to be 52.5% and 54.2%, respectively. Therefore, they can be applied to photodynamic / photothermal combined therapy.

[0026] (5) The type I photosensitizer nanoparticles prepared by the present invention have good light / thermal stability. After undergoing 4 heating / cooling cycles, their photothermal conversion capacity has almost no change, indicating that the fluorescent probe has good light / thermal stability.

[0027] (6) The type I photosensitizer nanoparticles prepared by the present invention have excellent biocompatibility, small toxic side effects, and have great application potential in the biomedical field.

[0028] (7) The type I photosensitizer nanoparticles prepared by the present invention are used for photodynamic / photothermal combined anti-tumor and antibacterial treatment. They can generate a large amount of reactive oxygen (·OH) and heat under laser irradiation, thereby effectively killing tumor cells and bacteria, showing good application prospects in phototherapy applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the hydrogen spectrum of the type I photosensitizer TPE-SQ6 of the present invention.

[0030] Figure 2 This is the hydrogen spectrum of the type I photosensitizer TPE-SQ7 of the present invention.

[0031] Figure 3 Schematic diagram of using F127 to encapsulate the type I photosensitizer of the present invention to prepare nanoparticles.

[0032] Figure 4 The absorption spectra (a) and average particle size change diagram (b) of the type I photosensitizer nanoparticles of the present invention after being placed for different time periods.

[0033] Figure 5 The fluorescence enhancement factor of DCFH (20 μM) as active oxygen indicator without or with the type I photosensitizer (5 μM) of the present invention and commercial photosensitizers Ce6 and RB at 525 nm was observed with the laser (635 nm, 0.50 W cm -2 ) is a comparison chart of the variation curve of irradiation time, where the excitation wavelength is 488nm.

[0034] Figure 6 The relative absorption intensity of ABDA (25 μM) at 378 nm wavelength was observed with laser (635 nm, 0.50 W cm) without or with the addition of the type I photosensitizer of the present invention (5 μM). -2 ) Curve diagram of the change of irradiation time.

[0035] Figure 7 The type I photosensitizer (5 μM) of the present invention is irradiated with laser (635 nm, 0.50 W cm -2 ) EPR pattern after irradiation for 5 min.

[0036] Figure 8 NBT (25 μM) was used as O2 - The indicator, without or with the type I photosensitizer of the present invention (5 μM), was used for laser (635 nm, 0.50 W cm -2 ) is a comparative bar graph of the relative absorption intensity at 260 nm before and after irradiation for 5 minutes.

[0037] Fig. 9 To use laser (635nm, 0.50W cm -2 ) irradiation, temperature rise curves of aqueous solutions of type I photosensitizer TPE-SQ6NPs (a) and TPE-SQ7NPs (b) of the present invention with different concentrations.

[0038] Fig.10 This is a photostability curve of the type I photosensitizer TPE-SQ6 NPs, TPE-SQ7 NPs and ICG (40 μM) of the present invention after four heating-cooling cycles.

[0039] Fig.11 The bar graph is a graph showing the cell viability detected by the CCK-8 method after NIH-3T3 cells were co-incubated with different concentrations of the type I photosensitizer TPE-SQ6 NPs (a) and TPE-SQ7 NPs (b) of the present invention for 24 hours.

[0040] Fig.12 Staphylococcus aureus (upper) and Escherichia coli (lower) in the presence or absence of the type I photosensitizer TPE-SQ6NPs, TPE-SQ7NPs (20μM) and / or laser (635nm, 0.5W cm -2 ) Photographs of colonies on agar culture plates under different treatment conditions.

[0041] Fig.13 Staphylococcus aureus (upper) and Escherichia coli (lower) in the presence or absence of the type I photosensitizer TPE-SQ6NPs, TPE-SQ7NPs (20μM) and / or laser (635nm, 0.5W cm -2 ) Histogram of bacterial survival rate under different treatment conditions.

[0042] Fig.14Staphylococcus aureus (upper) and Escherichia coli (lower) in the presence or absence of the type I photosensitizer TPE-SQ6NPs, TPE-SQ7NPs (20μM) and / or laser (635nm, 0.5W cm -2 ) under the scanning electron microscope (SEM) condition.

[0043] Fig.15 It is a bar graph of the survival rate of 4T1 cells with different concentrations of the type I photosensitizer TPE-SQ7 NPs of the present invention added under normoxic and hypoxic conditions.

[0044] Fig.16 It is a bar graph of the survival rate of 4T1 cells in different treatment groups under normoxic and hypoxic conditions.

[0045] Fig.17 These are photos of dead / live cell double staining experiments of 4T1 cells in different treatment groups under normoxic and hypoxic conditions.

[0046] Fig.18 Laser scanning confocal microscopy images of different treatment groups under normoxic and hypoxic conditions.

[0047] Fig.19 (a) The curve of changes in mouse body weight and (b) the growth curve of mouse tumor in different treatment groups.

[0048] Fig. 20 (a) Tumor mass bar graph and (b) tumor photos of mice in different treatment groups after treatment. DETAILED DESCRIPTION

[0049] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0050] The present invention provides a type I photosensitizer, which uses a tetraphenylethylene-substituted indoline derivative as a donor and a squaric acid as an acceptor; the structural formula of the photosensitizer is as follows:

[0051]

[0052] Wherein, R1 is selected from one of CH3, CH2SO3Na and CH2SO3K; R2 is selected from one of H, OCH3, -N(CH3)2 and -N(C6H5)2.

[0053] According to another aspect of the present invention, a method for preparing the type I photosensitizer based on squarylium cyanine is provided, comprising the following steps:

[0054] (1) Synthesis of type I photosensitizer TPE-SQ6 based on squaryl cyanine

[0055] 1-Butyl-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole and 3,4-dihydroxy-3-cyclobutene-1,2-dione are dissolved in an organic solvent A of benzene and alcohol, wherein the organic solvent A is a mixed solvent of organic solvent B and organic solvent C, wherein the organic solvent B is benzene, toluene or xylene, and the organic solvent C is propanol, n-butanol or n-pentanol; react at 100-140° C. under the protection of an inert gas; after sufficient reaction, extract and separate, dry the obtained organic phase, then remove the solvent by rotary evaporation under reduced pressure, separate and purify the product by column, and obtain a type I photosensitizer TPE-SQ6 based on squarylium cyanide having a structural formula shown in Formula III after drying:

[0056]

[0057] (2) Synthesis of type I photosensitizer TPE-SQ7 based on squaryl cyanine

[0058] Dissolve 1-(4-butylsulfonate)-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole and 3,4-dihydroxy-3-cyclobutene-1,2-dione in an organic solvent A of benzene and alcohol, wherein the organic solvent A is a mixed solvent of an organic solvent B and an organic solvent C, wherein the organic solvent B is benzene, toluene or xylene, and the organic solvent C is propanol, n-butanol or n-pentanol; and react at 100-140° C. under the protection of an inert gas. After sufficient reaction, the reaction solvent is removed by rotary evaporation under reduced pressure, and then column chromatography is performed; the obtained product is dissolved in an organic solvent D, wherein the organic solvent D is a mixed solvent of an organic solvent E and an organic solvent F, wherein the organic solvent E is dichloromethane, chloroform or tetrahydrofuran, and the organic solvent F is methanol, ethanol or acetone; a saturated aqueous solution of NaHCO3 or a saturated aqueous solution of Na2CO3 is added, and after sufficient stirring, the product is filtered under reduced pressure and dried to obtain a type I photosensitizer TPE-SQ7 based on squarylium cyanide having a structural formula as shown in Formula IV:

[0059]

[0060] Preferably, in step (1), the molar ratio of 1-butyl-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole and 3,4-dihydroxy-3-cyclobutene-1,2-dione is 1:(1 to 1.2), and the concentration of 1-butyl-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole in the mixed solution of organic solvent A is 1 mg / mL to 10 mg / mL.

[0061] Preferably, in step (2), the molar ratio of 1-(4-butylsulfonate)-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole and 3,4-dihydroxy-3-cyclobutene-1,2-dione is 1:(1 to 1.2), and the concentration of 1-(4-butylsulfonate)-2,3,3-trimethyl-5-(tetraphenylethylene)-3H-indole in organic solvent A is 1 mg / mL to 10 mg / mL.

[0062] According to another aspect of the present invention, there is provided the use of the type I photosensitizer based on squaraine for preparing a photodynamic / photothermal combined anti-tumor and antibacterial preparation.

[0063] Preferably, the type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide are added to an organic solvent miscible with water, added to water under ultrasonic conditions, and then ultrasonically treated to allow the type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide to self-assemble to obtain nanoparticles (NPs) of a core-shell structure, and then dialyzed to remove the organic solvent to obtain nanoparticles.

[0064] Preferably, the mass ratio of the type I photosensitizer based on squarylium cyanine to the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide is 1:(5-20); and the concentration of the nanoparticles is 0.1 mg / mL to 0.2 mg / mL.

[0065] The preparation method of the type I photosensitizer provided by the present invention has a preparation process as shown in the following formula:

[0066]

[0067] The preparation method comprises the following steps: Compound 1 and 3,4-dihydroxy-3-cyclobutene-1,2-dione are subjected to a condensation reaction to obtain a type I photosensitizer TPE-SQ6. Similarly, Compound 2 is subjected to a condensation reaction with 3,4-dihydroxy-3-cyclobutene-1,2-dione to obtain a product, which is then ionized with a saturated sodium bicarbonate aqueous solution to obtain a type I photosensitizer TPE-SQ7.

[0068] The method for preparing a type I photosensitizer based on squarylium cyanine of the present invention comprises the following steps:

[0069] (1) A certain amount of compound 1 and 3,4-dihydroxy-3-cyclobutene-1,2-dione are dissolved in an organic solvent A of benzene and alcohol, wherein the organic solvent A is a mixed solvent of organic solvent B and organic solvent C, wherein the organic solvent B is benzene, toluene or xylene, and the organic solvent C is propanol or n-butanol; react at 100-140° C. for a certain time (8-24 h) under the protection of an inert gas. After sufficient reaction, the reaction is purified to obtain a type I photosensitizer TPE-SQ6 based on squarylium cyanide having a structural formula as shown in Formula I.

[0070] (2) A certain amount of compound 2 and 3,4-dihydroxy-3-cyclobutene-1,2-dione are dissolved in an organic solvent A of benzene and alcohol, wherein the organic solvent A is a mixed solvent of organic solvent B and organic solvent C, wherein the organic solvent B is benzene, toluene or xylene, and the organic solvent C is propanol or n-butanol; the reaction is carried out at 100-140° C. for a certain time (8-24 h) under the protection of an inert gas. After sufficient reaction, the obtained product is purified, and then a saturated NaHCO3 aqueous solution or a saturated Na2CO3 aqueous solution is added to the obtained product, and after stirring at room temperature for a certain time, the obtained product is filtered, and the upper filter cake is washed with deionized water and then dried to obtain a type I photosensitizer TPE-SQ7 based on squarylium cyanide having a structural formula as shown in Formula I.

[0071] Type I photosensitizer TPE-SQ6 or TPE-SQ7 and a purchased commercial triblock polymer of ethylene oxide-propylene oxide-ethylene oxide (F127) were prepared into an organic solvent of a certain concentration (due to the difference in solubility, TPE-SQ6 is soluble in tetrahydrofuran, while TPE-SQ7 is soluble in N,N-dimethylformamide), and quickly added to water under ultrasonic conditions. After the addition is completed, ultrasonication is continued for 2 minutes, and then the solution is transferred to a dialysis bag (Mw=3500Da) and dialyzed for 24 hours. During this period, the water is replaced every 3-4 hours to obtain type I photosensitizer nanoparticles.

[0072] The type I photosensitizer provided by the present invention is used for photodynamic / photothermal combined antibacterial treatment. The type I photosensitizer and the surfactant F127 are self-assembled into nanoparticles, which are then internalized by bacteria. Even at a relatively low concentration (20 μM), the nanoparticles can be efficiently killed, and the bacteria and cancer cells are killed. This shows a good photodynamic / photothermal combined treatment effect, and has a good application prospect in anti-tumor and antibacterial treatment.

[0073] Example 1: Preparation of Type I photosensitizers TPE-SQ6 and TPE-SQ7

[0074] The specific steps are as follows:

[0075] (1) Synthesis of Type I photosensitizer TPE-SQ6:

[0076] Under N2 protection, compound 1 (0.20 g, 0.30 mmol) and squaric acid (0.015 g, 0.14 mmol) were added to the Dean-Stark apparatus, and then solvent-dried toluene (4 mL) and n-butanol (4 mL) were injected. The reaction was heated to reflux for 24 h and then cooled to room temperature. After removing the solvent using a rotary evaporator, the crude product was purified by column chromatography on silica gel (eluent: dichloromethane: ethyl acetate = 10:1) to obtain the product TPE-SQ6 as a blue-green solid (0.15 g, 94.7%). Figure 1 This is the hydrogen spectrum of the type I photosensitizer TPE-SQ6 prepared in this example. Specifically: 1 H NMR (600MHz, CDCl3, δ): 7.51 (s, 2H, ArH), 7.49 (d, J = 8.2Hz, 2H, ArH), 7.35 (d, J = 8.3Hz, 4H, ArH), 7.17-7.02 (m, 34H, ArH), 6.99 (d, J = 8.3Hz, 2H, ArH), 5.98(s,2H,-C=CH-),3.99(s,4H,-NCH2-),1.81(s,12H,-C(CH3)2),1.62- 1.55(m,4H,-CH2-), 1.47(qui,J=7.6Hz,4H,-CH2-), 0.99(t,J=7.4Hz,6H). 13 C NMR (100MHz, CDCl3, δ):169.8,143.6,142.7,141.9,141.2,140.4,138.3,136.6,131.9,131.4,127.8,12 7.7,127.6,126.5,126.4,126.0,120.8,109.5,87.0,49.3,43.7,29.2,27.2,20.4,13.9.HR-ESI-MS:m / z calcd.for C 86 H 76 N2O2:1169.59796[M+H + ], found1169.59819[M+H + ].

[0077] (2) Synthesis of Type I Photosensitizer TPE-SQ7

[0078] Under N2 protection, compound 2 (0.10 g, 0.16 mmol) and squaric acid (0.008 g, 0.07 mmol) were added to the Dean-Stark apparatus in sequence, and then solvent-dried toluene (3 mL) and n-butanol (3 mL) were injected. After the reaction was heated to reflux for 24 h, it was cooled to room temperature. After the solvent was removed by vacuum rotary evaporation, the crude product was purified by column chromatography on silica gel (eluent was dichloromethane: methanol = 10:1). Subsequently, the obtained product was dissolved in THF (10 mL), and methanol (2 mL) and saturated sodium bicarbonate aqueous solution (10 mL) were added. The mixed solution was stirred at room temperature for 2 h and then filtered under reduced pressure. After the upper product was washed with water several times, the product TPE-SQ7 was obtained as a dark green solid (0.07 g, 60.1%). Figure 1 This is the hydrogen spectrum of the type I photosensitizer TPE-SQ7 prepared in this example. Specifically: 1 H NMR (600MHz, CDCl3, δ): 7.82 (s, 2H, ArH), 7.61 (d, J = 8.3Hz, 2H, ArH), 7.54 (d, J = 8.4Hz, 4H, ArH), 7.39 (d, J = 8.5Hz, 2H, ArH ),7.23-7.10(m,18H,ArH),7.08-6.95(m,16H,ArH),5.81(s,2H,-C=CH-),4.09(s,4H,-NCH2-),2.50-2.46(m,4H,-CH2SO3 – ),1.85-1.75(m,4H,-CH2-),1.71(s,12H,-C(CH3)2),1.26(m,4H,-CH2-). 13 C NMR (100MHz, CDCl3, δ):178.7,169.3,143.8,143.7,142.8,142.4,142.3,141.1,140.6,138.2,135.5,131.7,131.2,13 1.1,128.5,128.3,128.3,127.2,127.1,126.2,120.8,111.2,86.9,51.3,49.3,43.6,27.0,26.4,23.1.HR-ESI-MS:m / z calcd.for C 86 H 74 N2O8S2Na2:663.24488[m / z],found663.24504[m / z].

[0079] Example 2: Preparation of Type I Photosensitizer TPE-SQ6 and TPE-SQ7 Nanoparticles

[0080] Take TPE-SQ6 or TPE-SQ7 (1.0 mmol) and the purchased commercial surfactant poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Pluronic F127) (15 mg) and dissolve them in 1.0 mL of organic solvent (in view of the difference in solubility, TPE-SQ6 is dissolved in tetrahydrofuran, i.e. THF, and TPE-SQ7 is dissolved in N,N-dimethylformamide, i.e. DMF). When the sample is completely dissolved, it is quickly added to 10 mL of deionized water. During this period, a probe sonicator is used to continuously sonicate for 2 minutes (output power: 50%) to form NPs. Then, the solution is transferred to a dialysis bag (MWCO: 3500Da) and dialyzed with deionized water for 24 hours. The deionized water is replaced every 3-4 hours to completely remove THF or DMF. After the dialysis is completed, ratiometric fluorescent probe nanoparticles of uniform size are obtained. The schematic diagram of its preparation method is shown in Figure 3 .

[0081] Example 3: Long-term stability of type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles

[0082] Take two 5 mL sample bottles, add 0.3 mL of the solution of TPE-SQ6 and TPE-SQ7 nanoparticles obtained in Example 2 (the concentration of the original solution of the fluorescent probe is 0.1 mM), and then add 2.7 mL of aqueous solution, and stir at room temperature for 2 minutes. Then use a UV-visible spectrophotometer and a particle size analyzer to test the absorption spectrum and average particle size. Figure 4 The test results show that the absorption spectra and average particle sizes of aqueous solutions of TPE-SQ6 and TPE-SQ7 nanoparticles remain almost unchanged after being placed for 15 days, showing good long-term stability.

[0083] Example 4: Evaluation of the photodynamic properties of type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles

[0084] (1) Detection of total reactive oxygen species (ROS)

[0085] 2',7'-dichlorofluorescein diacetate (DCFH-DA) was used as an indicator to detect the generation of ROS. After DCFH-DA reacted with ROS, the green fluorescence gradually increased, and its maximum emission wavelength was 525nm. The specific method was as follows: take DCFH-DA (0.5mL, 10 -3 M) ethanol solution was added to a concentration of 10 -2 M NaOH (2 mL) aqueous solution, stirred at room temperature for 30 min. Then 10 mL of PBS (1×, pH = 7.4) solution was added to obtain a concentration of 4×10 -5M 2',7'-dichlorodihydrofluorescein (DCFH) solution, store in dark until use. Take 1.5 mL of the above DCFH (4×10 -5 M) solution was transferred to a 4 mL sample bottle, and then TPE-SQ6 NPs or TPE-SQ7 NPs (0.15 mL, 10 -4 M) and PBS (1.35 mL, 1×, pH = 7.4) solution. After being fully shaken, the fluorescence spectrum was tested. Then, a laser (635 nm, 0.5 W cm -2 ) for 30 seconds each time and record its fluorescence spectrum for a total of 5 minutes. Calculate the ratio of the fluorescence intensity at 525 nm after illumination to the initial fluorescence intensity (I / I0-1) versus illumination time. Figure 5 The measurement results show that: with the increase of laser irradiation time, the fluorescence intensity of the DCFH probe at 525nm increases significantly, indicating that TPE-SQ6 and TPE-SQ7 NPs have good ROS generation ability. In addition, compared with the commercial photosensitizers dihydrochlorin e6 (Ce6) and Rose bengal (Rose bengal, RB), the type I photosensitizers TPE-SQ6 and TPE-SQ7 NPs of the present invention have better ROS generation ability.

[0086] (2) Singlet oxygen ( 1 O2) detection

[0087] 9,10-Anthracenediyl-bis(methylene)dicarboxylic acid (ABDA) was used as an indicator for detection 1 O2 production, 1 O2 will react with ABDA and cause its characteristic absorption peak at 378nm to decrease. The specific method is: prepare a concentration of 5×10 -5 Then, 1.5 mL of the ABDA solution was transferred to a 4 mL sample bottle. Then, TPE-SQ6 NPs or TPE-SQ7 NPs (0.15 mL, 10 -4 M) and 1.35 mL of PBS (1×, pH = 7.4) solution. After thorough shaking, the absorption spectrum was tested. Then, a laser (635 nm, 0.5 W cm -2 ) for 30 seconds each time and record its absorption spectrum for a total of 5 minutes. Calculate the ratio of the absorption value at 378nm after illumination to the initial absorption value (A / A0) versus illumination time. Figure 6 The results show that after laser irradiation, the ratio of the absorption value at 378nm to the initial absorption value did not change significantly, indicating that there is no 1The production of O2 indicates that TPE-SQ6 and TPE-SQ7 NPs are not type II photosensitizers.

[0088] (3) Detection of hydroxyl radicals (·OH)

[0089] Electron paramagnetic resonance (EPR) test: 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) was used as a free radical scavenger to test the free radical activity of TPE-SQ6 NPs or TPE-SQ7 NPs under laser (635 nm, 0.5 W cm -2 ) to determine whether free radicals will be generated under irradiation. The specific method is as follows: first, take TPE-SQ6 NPs or TPE-SQ7 NPs (15 μL, 10 -4 M) was transferred to a 1.5 mL centrifuge tube, and then 285 μL of deionized water and 30 μL of DMPO were added. After thorough shaking, it was tested as a control group. Then, a laser (635 nm, 0.5 W cm -2 ) irradiated the solution for 5 minutes and then tested it as the experimental group. Figure 7 The test results show that after 5 minutes of laser irradiation, obvious signal peaks were generated in the aqueous solutions of TPE-SQ6 and TPE-SQ7 NPs containing DMPO, and the ratio was 1:2:2:1, indicating that the type of ROS generated was ·OH, thus proving that TPE-SQ6 and TPE-SQ7 are type I photosensitizers.

[0090] (4) Superoxide anion free radical (·O2 - )

[0091] Nitro blue tetrazolium chloride (NBT) was used as an indicator to detect the presence of O2 - The generation of O2 - It will react with NBT and cause its characteristic absorption peak at 260nm to decrease. The specific method is: prepare a concentration of 5×10 -5 Then, 1.5 mL of the above solution was transferred to a 4 mL sample bottle. Then, TPE-SQ6 NPs or TPE-SQ7 NPs (0.15 mL, 10 -4 M) and 1.35 mL of PBS (1×, pH = 7.4) solution. After thorough shaking, the absorption spectrum was tested. Then, a laser (635 nm, 0.5 W cm -2 ) irradiate the solution for 5 minutes, and then record its absorption spectrum. Calculate the ratio of the absorption value at 260nm after irradiation to the initial absorption value (A / A0) versus the irradiation time. Figure 8The test results show that after 5 minutes of laser irradiation, the ratio of the absorption value at 260nm in the solution to the initial absorption value has no significant change, which indicates that no O2 is generated in the system. - .

[0092] Example 5: Photothermal performance evaluation of type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles

[0093] The TPE-SQ6 and TPE-SQ7 NPs in Example 2 were diluted to different concentrations (0, 5, 10, 20, and 40 μM) using deionized water, and 1 mL of each was transferred to a 1.5 mL centrifuge tube. -2 ) and use a thermal imager to record temperature changes. Record once every 30 seconds, and the total illumination time for each group is 5 minutes. Deionized water was used as the control group under the same conditions. Fig. 9 The test results show that: under laser (635nm, 0.50W cm -2 ), the temperature of their aqueous solutions rose rapidly, and the higher the concentration, the faster the temperature rose. After 5 minutes of irradiation, the solution temperature of TPE-SQ6 and TPE-SQ7 NPs (40μM) rose to 50.9℃ and 55℃, respectively, indicating that TPE-SQ6 and TPE-SQ7 NPs have good photothermal conversion capabilities.

[0094] Example 6: Photostability evaluation of type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles

[0095] TPE-SQ6 and TPE-SQ7 NPs (40 μM) in Example 2 were prepared respectively, and 1 mL of each was transferred to a 1.5 mL centrifuge tube. -2 ) was irradiated, and the data was recorded every 30 seconds using a thermal imager. The total illumination time for each group was 5 minutes. After stopping the illumination, the temperature was calculated as one cycle until the solution returned to the initial temperature. Repeat the recording for 4 cycles, see Fig.10 The test results show that after four heating / cooling cycles, the temperature change curves of both NPs show almost no attenuation. In contrast, the photothermal conversion ability of indocyanine green (ICG) under the same conditions has been significantly attenuated, indicating that TPE-SQ6 and TPE-SQ7 NPs have good photostability.

[0096] Example 7: Evaluation of the dark cytotoxicity of type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles

[0097] The biocompatibility of TPE-SQ6 and TPE-SQ7 NPs was evaluated by using the CCK-8 method (Cell Counting Kit-8). Specific experimental steps: Different concentrations of TPE-SQ6 and TPE-SQ7 NPs (0, 2.5, 5, 10 and 20 μM) in Example 2 were prepared and added to NIH-3T3 cells for co-incubation for 24 h, and the cell survival rate was observed. Fig.11 The test results showed that when the NPs concentration increased to 20 μM, the cell survival rate was still over 90%, indicating that both NPs have good biocompatibility and low cytotoxicity, which will be beneficial for their biomedical applications.

[0098] Example 8: Type I photosensitizer TPE-SQ6 and TPE-SQ7 nanoparticles for photodynamic / photothermal combined antibacterial

[0099] Taking Staphylococcus aureus and Escherichia coli as representatives of Gram-positive bacteria and Gram-negative bacteria respectively, the photodynamic / photothermal combined antibacterial effects of TPE-SQ6 and TPE-SQ7 nanoparticles prepared in Example 2 were systematically studied. Specific experimental steps: First, take a single colony (first generation) of the above two bacteria and inoculate it in Luria-Bertani (LB) medium, culture it in a shaker at 120rpm and 37°C overnight to obtain the second generation of bacteria. Subsequently, the second generation of bacteria was diluted 100 times with LB medium, transferred to an environmental shaker at 37°C and cultured for 4 hours. Use a UV-visible spectrophotometer to measure the absorbance (OD 600 nm ) and adjusted to 0.5. Then, take an appropriate amount of bacterial suspension (OD 600 nm =1.0) was added to the diluted TPE-SQ6 and TPE-SQ7 NPs (20 μM) solution and stabilized for 1 min before being illuminated using a laser (635 nm, 0.50 W cm -2 ) irradiated for 15 min as the experimental group. The bacteria without TPE-SQ6 NPs, TPE-SQ7 NPs and light were used as the control group. In addition, the bacterial suspension treated with only NPs or laser was used as the comparative experimental group. Then, the obtained bacterial suspension was diluted 10 4 Take 100 μL of the diluted bacterial suspension and inoculate it on LB agar medium, and transfer it to a constant temperature incubator at 37°C and culture it for 18 hours. Take a picture of the culture dish and count the number of colonies formed. Fig.12 and Fig.13The test results showed that neither the control group nor the comparative experimental group showed significant bactericidal ability. However, when the bacteria were treated with TPE-SQ6 NPs (20 μM) or TPE-SQ7 NPs (20 μM) and irradiated with laser for 15 minutes, Staphylococcus aureus was completely killed, with an antibacterial rate of 100%, and the antibacterial rates for Escherichia coli were 95.7% and 98.4%, respectively. In addition, the scanning electron microscopy results of the antibacterial experiment are shown in Fig.14 The test results show that in the control group and the comparative experimental group, the bacteria have clear edges and complete morphology, but when TPE-SQ6 NPs or TPE-SQ7NPs are treated and irradiated with laser, the bacteria are severely damaged and ruptured (the arrows in the figure), eventually leading to bacterial death. These results show that both TPE-SQ6 and TPE-SQ7NPs have good photodynamic / photothermal combined antibacterial capabilities and show good application prospects in broad-spectrum antibacterial.

[0100] Example 9: Evaluation of the killing effect of type I photosensitizer TPE-SQ7 nanoparticles on 4T1 cells

[0101] To evaluate the photodynamic / photothermal combined therapeutic effect of TPE-SQ7 NPs prepared in Example 2, 4T1 cells were cultured in 96-well plates under normoxic (21% O2) or hypoxic (1% O2) conditions for 24 hours. Then, the culture medium was replaced with 100 μL DMEM containing different concentrations of TPE-SQ7 NPs under normoxic (21% O2) or hypoxic (1% O2) conditions and incubated for 4 hours. Afterwards, the cells were replaced with fresh DMEM sealed in an anaerobic bag (1% O2) and irradiated with a 635 nm laser (0.5 W cm -2 ) for 5 minutes. After further incubation for 12 hours, cell viability was examined by cell counting kit-8 (CCK-8) assay, see Fig.15 In addition, under the same conditions, the cell viability of different treatment groups (control group, laser group, TPE-SQ7 NPs group, Ce6+laser group and TPE-SQ7 NPs+laser group) was also compared. Fig.16 At the same time, the relevant dead / live cell double staining experiment photos can be found in Fig.18 The test results show that TPE-SQ7 nanoparticles exhibit concentration-dependent phototoxicity; at a concentration of 30 μM, the survival rate of 4T1 cells under normoxic conditions was only 15.2%, and the survival rate under hypoxic conditions was 18.9%, indicating that the type I photosensitizer TPE-SQ7 NPs of the present invention can still effectively kill 4T1 cells under hypoxic conditions. In addition, the photos of the double staining experiment of dead / live cells are shown in Fig.17The results further intuitively demonstrated that TPE-SQ7 NPs still have excellent killing effect on 4T1 cells under hypoxic conditions.

[0102] Example 10: Evaluation of the production of reactive oxygen species by type I photosensitizer TPE-SQ7 nanoparticles in mouse breast cancer cells

[0103] Using dichlorodihydrofluorescein-acetoacetate (DCFH-DA) as a reactive oxygen species indicator, 4T1 cells were cultured in a 96-well plate for 8 h, then transferred to an anaerobic bag at 37°C for another 4 h and divided into five groups: (1) control group, (2) laser group, (3) TPE-SQ7 NPs group, (4) Ce6+laser group, and (5) TPE-SQ7 NPs+laser group. A 2 mm piece of agarose gel was embedded in each well, and the DCFH-DA probe was added and incubated for 30 min, then treated with different groups and sealed in an anaerobic bag (1% O2) at 37°C for another 30 min. Subsequently, a 635 nm laser (0.5 W cm -2 After 0.5 h of incubation, the cells were washed three times with PBS and observed under a fluorescence microscope. Fig.18 . The test results showed that light-irradiated TPE-SQ7NPs produced bright green fluorescence in 4T1 cells under both normoxic and hypoxic conditions, indicating that TPE-SQ7 NPs can effectively produce reactive oxygen species in 4T1 cells. The commercial photosensitizer Ce6 can only produce reactive oxygen species under normoxic conditions. In addition, the control group, laser group, and TPE-SQ7 NPs that were not irradiated by laser did not show green fluorescence, indicating that the source of reactive oxygen species is TPE-SQ7 NPs, and light is a necessary condition for photosensitizers to produce reactive oxygen species.

[0104] Example 11: Photodynamic / photothermal combined anti-tumor therapy of type I photosensitizer TPE-SQ7 nanoparticles in mice

[0105] The TPE-SQ7 NPs prepared in Example 2 were injected into 4T1 tumor-bearing mice via the tail vein, and the mice injected with PBS were used as the control group. The 4T1 tumor-bearing mice were randomly divided into five groups (3 mice in each group), namely: (1) control group, (2) laser group, (3) TPE-SQ7 NPs group, (4) Ce6+laser group, and (5) TPE-SQ7 NPs+laser group. For groups (2), (4) and (5), 635 nm laser (0.5 W cm -2 The tumor site was irradiated with 100 μg / mL of light for 5 minutes. The weight and tumor volume of the mice were measured every other day until the 16th day when the tumors of 4T1 tumor-bearing mice were dissected out and photographed with a camera. Fig.19 and Fig. 20 As shown. The test results show that during the treatment period, the TPE-SQ7 NPs + laser group had a significant inhibitory effect on tumor growth, reaching a tumor inhibition rate of 94.4%, showing a very efficient photodynamic / photothermal combined treatment effect. In contrast, the commercial type II photosensitizer Ce6 + light group showed a poor effect in inhibiting tumor growth; in the hypoxic environment of the tumor, the oxygen-dependent type II photodynamic anti-tumor effect is not ideal. In addition, the other groups could not inhibit tumor growth.

[0106] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A type I photosensitizer based on squarylium cyanine, characterized in that: The type I photosensitizer uses a tetraphenylethylene-substituted indoline derivative as a donor and a squaric acid as an acceptor; the structural formula of the type I photosensitizer is shown in formula I: Wherein, R1 is selected from one of CH3, CH2SO3Na and CH2SO3K; R2 is selected from one of H, OCH3, -N(CH3)2 and -N(C6H5)2.

2. The method for preparing a type I photosensitizer based on squarylium cyanine according to claim 1, characterized in that: The following steps are involved: (1) dissolving the compound of formula II and 3,4-dihydroxy-3-cyclobutene-1,2-dione in a mixed organic solvent, wherein the mixed organic solvent is a mixed solvent of a benzene organic solvent and an alcohol organic solvent; (2) reacting the mixed solvent obtained in step (1) at 100-140° C., and after sufficient reaction, purifying the mixed solvent. When R1 is CH2SO3Na or CH2SO3K, it is also necessary to undergo sodium ionization or potassium ion treatment accordingly, thereby obtaining a type I photosensitizer based on squarylium cyanide having a structural formula as shown in Formula I; Wherein, R1 is selected from one of CH3, CH2SO3Na and CH2SO3K; R2 is selected from one of H, OCH3, -N(CH3)2 and -N(C6H5)2.

3. The method for preparing a type I photosensitizer based on squarylium cyanine according to claim 2, characterized in that: The benzene organic solvent is benzene, toluene or xylene, and the alcohol organic solvent is propanol, n-butanol or n-pentanol.

4. The method for preparing a type I photosensitizer based on squarylium cyanine according to claim 2 or 3, characterized in that: The molar ratio of the compound of formula II to 3,4-dihydroxy-3-cyclobutene-1,2-dione is (2-2.4):

1.

5. The method for preparing a type I photosensitizer based on squarylium cyanine according to claim 2 or 3, characterized in that: The concentration of the compound of formula II in the mixed organic solvent is 1 mg / mL to 10 mg / mL.

6. The method for preparing a type I photosensitizer based on squarylium cyanine according to claim 2 or 3, characterized in that: In step (2), the reaction time is 8-24 hours.

7. The use of the type I photosensitizer based on squaraine as claimed in claim 1 for preparing a photodynamic and photothermal combined anti-tumor preparation or a photodynamic and photothermal combined antibacterial preparation, characterized in that: The type I photosensitizer based on squaraine is assembled to obtain nanoparticles with a core-shell structure.

8. The use according to claim 7, characterized in that The type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide are added to an organic solvent miscible with water, added to water under ultrasonic conditions, and then ultrasonically treated to assemble the type I photosensitizer based on squaryl cyanine and the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide to obtain nanoparticles with a core-shell structure, and then dialyzed to remove the organic solvent to obtain a mixed system of nanoparticles and water.

9. The use according to claim 8, characterized in that The mass ratio of the type I photosensitizer based on squarylium cyanine to the triblock polymer of ethylene oxide-propylene oxide-ethylene oxide is 1:(2-20).

10. The use according to claim 8, characterized in that The concentration of the nanoparticles in the mixed system is 0.1 mg / mL to 0.2 mg / mL.

Citation Information

Patent Citations

  • Squaraine-based ratio type fluorescent probe as well as preparation method and application thereof

    CN113563249A

  • AIE heptamethine cyanine photosensitizer for bimodal imaging and diagnosis and treatment as well as preparation method and application of AIE heptamethine cyanine photosensitizer

    CN117986182A

  • Preparation method and application of photosensitizer for type I photodynamic therapy and photothermal therapy

    CN118108739A